SERA PROGNOSTICS INC-A (SERA)
US81749D1072 - Common Stock
SERA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. SERA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SERA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SERA has reported negative net income.
SERA had a negative operating cash flow in the past year.
In the past 5 years SERA always reported negative net income.
In the past 5 years SERA always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -37.98%, SERA is in the better half of the industry, outperforming 62.67% of the companies in the same industry.
SERA's Return On Equity of -51.66% is fine compared to the rest of the industry. SERA outperforms 67.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.98% | ||
| ROE | -51.66% | ||
| ROIC | N/A |
ROA(3y)-33.26%
ROA(5y)-60.96%
ROE(3y)-40.53%
ROE(5y)-214%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 32.23%, SERA is doing good in the industry, outperforming 77.57% of the companies in the same industry.
In the last couple of years the Gross Margin of SERA has declined.
The Profit Margin and Operating Margin are not available for SERA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 32.23% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2%
GM growth 5YN/A
2. Health
2.1 Basic Checks
SERA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SERA has been increased compared to 1 year ago.
SERA has a better debt/assets ratio than last year.
2.2 Solvency
SERA has an Altman-Z score of 3.43. This indicates that SERA is financially healthy and has little risk of bankruptcy at the moment.
SERA has a better Altman-Z score (3.43) than 77.23% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that SERA is not too dependend on debt financing.
The Debt to Equity ratio of SERA (0.00) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.43 |
ROIC/WACCN/A
WACC9.33%
2.3 Liquidity
SERA has a Current Ratio of 2.51. This indicates that SERA is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.51, SERA is not doing good in the industry: 73.29% of the companies in the same industry are doing better.
A Quick Ratio of 2.51 indicates that SERA has no problem at all paying its short term obligations.
SERA has a worse Quick ratio (2.51) than 71.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.51 | ||
| Quick Ratio | 2.51 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 18.88% over the past year.
Looking at the last year, SERA shows a small growth in Revenue. The Revenue has grown by 7.50% in the last year.
SERA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 116.87% yearly.
EPS 1Y (TTM)18.88%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q19.35%
Revenue 1Y (TTM)7.5%
Revenue growth 3Y116.87%
Revenue growth 5YN/A
Revenue growth Q2Q-41.43%
3.2 Future
Based on estimates for the next years, SERA will show a decrease in Earnings Per Share. The EPS will decrease by -0.95% on average per year.
SERA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 292.71% yearly.
EPS Next Y11.19%
EPS Next 2Y6.9%
EPS Next 3Y-0.95%
EPS Next 5YN/A
Revenue Next Year26.76%
Revenue Next 2Y410.45%
Revenue Next 3Y292.71%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SERA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SERA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.9%
EPS Next 3Y-0.95%
5. Dividend
5.1 Amount
No dividends for SERA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SERA PROGNOSTICS INC-A
NASDAQ:SERA (4/26/2024, 7:15:42 PM)
10.75
+0.41 (+3.97%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap348.62M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.98% | ||
| ROE | -51.66% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 32.23% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.51 | ||
| Quick Ratio | 2.51 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)18.88%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y11.19%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)7.5%
Revenue growth 3Y116.87%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y